Barclays downgraded Exelixis to Equal Weight from Overweight with an unchanged price target of $25. The analyst cites a lack of near-to-mid term catalysts for the downgrade, saying investors are
Barclays downgraded Exelixis to Equal Weight from Overweight with an unchanged price target of $25. The analyst cites a lack of near-to-mid term catalysts for the downgrade, saying investors are
הסיבה לשינוי זה היא שאין הרבה אירועים שצפויים בקרוב שיכולים להגדיל באופן משמעותי את ערכו של מניית החברה. האנליסט מאמין שיש מניות אחרות שעשויות להציע תשואות טובות יותר. גם כן,
Barclays analyst Peter Lawson downgraded Exelixis (EXEL – Research Report) to a Hold today and set a price target of $25.00. The company’s shares closed yesterday at $23.68. According to
JMP Securities analyst Silvan Tuerkcan has maintained their bullish stance on EXEL stock, giving a Buy rating on April 4. Silvan Tuerkcan has given his Buy rating due to a
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Surrozen (SRZN – Research Report), Exelixis (EXEL – Research Report) and Axsome Therapeutics (AXSM – Research Report) with bullish sentiments.
Surrozen (SRZN)
In a report released yesterday, Dae Gon Ha from Stifel Nicolaus maintained a Buy rating on Surrozen, with a price target of $33.00. The company’s shares closed last Monday at $11.23.
According to TipRanks.com, Ha is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Surrozen with a $33.00 average price target.
See the top stocks recommended by analysts >>
Exelixis (EXEL)
RBC Capital analyst Gregory Renza maintained a Buy rating on Exelixis on April 4 and set a price target of $28.00. The company’s shares closed last Monday at $23.35, close to its 52-week high of $24.34.
According to TipRanks.com, Renza is a 5-star analyst with an average return of
Currently, the analyst consensus on Exelixis is a Strong Buy with an average price target of $26.75, a 16.2% upside from current levels. In a report issued on March 21, Citi also maintained a Buy rating on the stock with a $31.00 price target.
Axsome Therapeutics (AXSM)
RBC Capital analyst Leonid Timashev maintained a Buy rating on Axsome Therapeutics on April 4 and set a price target of $127.00. The company’s shares closed last Monday at $72.11.
According to TipRanks.com, Timashev is a 4-star analyst with an average return of
Axsome Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $125.33, representing a 73.9% upside. In a report issued on March 25, Leerink Partners also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SRZN: